|
Regenesis Biomedical, a Scottsdale-based medical device company, has initiated a multi-center, randomized clinical trial assessing the Provant® Therapy System for relieving symptoms of painful diabetic distal symmetric peripheral neuropathy (DSPN).
Research by Barrow Neurological Institute physicians and University of Washington scientists on novel imaging technology for malignant brain tumors was published in the April issue of World Neurosurgery.
Banner Health has announced Francisco Arabia, MD, an internationally recognized surgeon and executive leader in thoracic, cardiothoracic vascular and transplant surgery, has joined the organization.
Rapid, non-invasive diagnosis assisted by TGen assay could be used to help detect many types of cancer
Iluminos Therapeutics has licensed new compounds designed to treat neurodegenerative diseases, particularly Alzheimer’s.
Megha Padi, Ph.D., of the UA Cancer Center has developed a method for probing the genetic underpinnings of cancer and other diseases, which could lead to better treatments
Through a process known as strand displacement, a tiny walking device composed of DNA moves across a surface in a cartwheeling motion. The new device performed this feat more rapidly than any DNA walker designed to date.
Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autism
Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (AEM-28 and analogs) for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. LipimetiX is approximately 60%-owned by Capstone Therapeutics Corp.
Precision medicine is one of the fastest growing fields of medicine, turning the “one-size fits all” approach of healthcare on its head. Precision medicine is a specialized area of medicine that integrates genetic and genomic knowledge with data on environmental and lifestyle influences to individualize and refine care of patients and populations.
The non‑exclusive license and supply agreement will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders.
Critical Path Institute’s Patient-Reported Outcome Consortium announces its second clinical outcome assessment qualification from the US Food and Drug Administration
Study will evaluate safety and efficacy of company’s CBD product candidate in rare genetic disease characterized by insatiable appetite in childrenContinue reading
Study aims to develop the first predictive test to identify and prevent necrotizing enterocolitis, a disease that kills thousands of premature babies each year.
|
